Jimmy Weterings

FAQ About Jimmy Weterings

• What is Jimmy Weterings's address?

  Jimmy Weterings is located at
  Germantown, Maryland, United States

• What is Jimmy Weterings's job title?

  Jimmy Weterings is a
  Jim Weterings, PhD is Vice President, R&D, USA at Sirnaomics where he is dedicated to bring novel (targeted) RNAi therapeutics to patients. Working across Sweden, the Netherlands, Belgium, Germany and USA, Jim previously worked for AstraZeneca, Cristal Therapeutics and Cenix BioScience where he led the setup and growth of biotech & pharma organizations, provided leadership, synthesis and bioconjugation expertise for various (targeted) oligonucleotide research and clinical programs. Identified diverse delivery technologies, coordinated external collaborations, and contributed to IP generation/protection and innovation strategies within cross-functional teams. In total, he now has more than 20 years of experience in the oligonucleotide therapeutics field. Jim holds several patents for drug delivery enabling technologies, including TMTHSI (registered CliCr), a new “golden standard” conjugation compound for antibody drug and oligonucleotide conjugates. This compound provided critical freedom-to-operate and revenue in this space to Cristal Tx. In 2022, CliCr was exclusively licensed to Synaffix to develop "Best-in-Class" Antibody Drug Conjugates (ADC). In 2023 Lonza initiated a collaboration with Cristal Tx on CliCr. Iris Biotech GmbH has made CliCr commercially available under licensed agreement with Cristal Tx. In addition to the patents, Jim (co)authored 13 peer-reviewed papers. In the public domain, Jim is an active advocate for the awareness and use of oligonucleotide therapeutics to cure diseases with unmet need. Jim contributes regularly as invited speaker, chair or panel lead at internationally renowned oligonucleotide therapeutic conferences. In addition he hosts a biannual TIDES training series workshop on targeted delivery of Oligonucleotides. As advisory board member, he contributes to a balanced agenda at TIDES Europe, SAE Oligonucleotide Therapeutics & Delivery and Oxford Biologics series: all yearly occurring oligonucleotide/peptide therapeutic conferences. Sirnaomics

• What industry does Jimmy Weterings currently work in?

  Jimmy Weterings currently works in the
  Sirnaomics

• What is Jimmy Weterings's area of expertise?

  Jimmy Weterings specializes in
  Jim Weterings, PhD is Vice President, R&D, USA at Sirnaomics where he is dedicated to bring novel (targeted) RNAi therapeutics to patients. Working across Sweden, the Netherlands, Belgium, Germany and USA, Jim previously worked for AstraZeneca, Cristal Therapeutics and Cenix BioScience where he led the setup and growth of biotech & pharma organizations, provided leadership, synthesis and bioconjugation expertise for various (targeted) oligonucleotide research and clinical programs. Identified diverse delivery technologies, coordinated external collaborations, and contributed to IP generation/protection and innovation strategies within cross-functional teams. In total, he now has more than 20 years of experience in the oligonucleotide therapeutics field. Jim holds several patents for drug delivery enabling technologies, including TMTHSI (registered CliCr), a new “golden standard” conjugation compound for antibody drug and oligonucleotide conjugates. This compound provided critical freedom-to-operate and revenue in this space to Cristal Tx. In 2022, CliCr was exclusively licensed to Synaffix to develop "Best-in-Class" Antibody Drug Conjugates (ADC). In 2023 Lonza initiated a collaboration with Cristal Tx on CliCr. Iris Biotech GmbH has made CliCr commercially available under licensed agreement with Cristal Tx. In addition to the patents, Jim (co)authored 13 peer-reviewed papers. In the public domain, Jim is an active advocate for the awareness and use of oligonucleotide therapeutics to cure diseases with unmet need. Jim contributes regularly as invited speaker, chair or panel lead at internationally renowned oligonucleotide therapeutic conferences. In addition he hosts a biannual TIDES training series workshop on targeted delivery of Oligonucleotides. As advisory board member, he contributes to a balanced agenda at TIDES Europe, SAE Oligonucleotide Therapeutics & Delivery and Oxford Biologics series: all yearly occurring oligonucleotide/peptide therapeutic conferences.

• Which languages does Jimmy Weterings speak? 

  Jimmy Weterings speaks the following languages:
  No languages available.

• Which industries has Jimmy Weterings previously worked in?   

  Jimmy Weterings has prior experience in the following industries:
  Sirnaomics , Astrazeneca , Astrazeneca , Cristal Therapeutics , Cristal Therapeutics , Emultech , Cenix Bioscience , Vrije Universiteit Amsterdam , Leiden University , Prosensa , Leiden University , Akzo Nobel

• What is Jimmy Weterings’s work experience?  

  Jimmy Weterings has the following professional experience:
  Sirnaomics , Oxford Global Conferences Oligonucleotide Chemistry And Tx Europe , Sirnaomics , Sae Media Oligonucleotide Therapeutics And Delivery , Astrazeneca , Tides Oligonucleotides And Peptides , Astrazeneca , Cristal Therapeutics , Cristal Therapeutics , Emultech , Cenix Bioscience , Vrije Universiteit Amsterdam , Leiden University , Prosensa , Leiden University , Akzo Nobel .

• How can I find Jimmy Weterings on LinkedIn?  

  You can view Jimmy Weterings’s
  LinkedIn profile at LinkedIn URL.

• What are Jimmy Weterings’s work email addresses?  

  Jimmy Weterings’s work email addresses are
  [email protected] .

• What company does Jimmy Weterings work for?  

  Jimmy Weterings works at
  Sirnaomics